Kiniksa Pharmaceuticals (KNSA) Competitors $21.21 +0.39 (+1.87%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends KNSA vs. OCUL, INVA, ARQT, SUPN, PLRX, BPMC, NUVL, VKTX, LNTH, and RNAShould you be buying Kiniksa Pharmaceuticals stock or one of its competitors? The main competitors of Kiniksa Pharmaceuticals include Ocular Therapeutix (OCUL), Innoviva (INVA), Arcutis Biotherapeutics (ARQT), Supernus Pharmaceuticals (SUPN), Pliant Therapeutics (PLRX), Blueprint Medicines (BPMC), Nuvalent (NUVL), Viking Therapeutics (VKTX), Lantheus (LNTH), and Avidity Biosciences (RNA). These companies are all part of the "medical" sector. Kiniksa Pharmaceuticals vs. Ocular Therapeutix Innoviva Arcutis Biotherapeutics Supernus Pharmaceuticals Pliant Therapeutics Blueprint Medicines Nuvalent Viking Therapeutics Lantheus Avidity Biosciences Ocular Therapeutix (NASDAQ:OCUL) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability. Does the media refer more to OCUL or KNSA? In the previous week, Ocular Therapeutix had 14 more articles in the media than Kiniksa Pharmaceuticals. MarketBeat recorded 14 mentions for Ocular Therapeutix and 0 mentions for Kiniksa Pharmaceuticals. Kiniksa Pharmaceuticals' average media sentiment score of 0.49 beat Ocular Therapeutix's score of 0.40 indicating that Kiniksa Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Ocular Therapeutix Neutral Kiniksa Pharmaceuticals Neutral Does the MarketBeat Community prefer OCUL or KNSA? Ocular Therapeutix received 266 more outperform votes than Kiniksa Pharmaceuticals when rated by MarketBeat users. Likewise, 70.10% of users gave Ocular Therapeutix an outperform vote while only 64.89% of users gave Kiniksa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformOcular TherapeutixOutperform Votes43670.10% Underperform Votes18629.90% Kiniksa PharmaceuticalsOutperform Votes17064.89% Underperform Votes9235.11% Which has more volatility and risk, OCUL or KNSA? Ocular Therapeutix has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Which has stronger valuation & earnings, OCUL or KNSA? Kiniksa Pharmaceuticals has higher revenue and earnings than Ocular Therapeutix. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcular Therapeutix$58.44M23.62-$80.74M-$1.32-6.65Kiniksa Pharmaceuticals$384.10M3.99$14.08M-$0.14-151.50 Do insiders and institutionals believe in OCUL or KNSA? 59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. 3.5% of Ocular Therapeutix shares are held by insiders. Comparatively, 54.6% of Kiniksa Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is OCUL or KNSA more profitable? Kiniksa Pharmaceuticals has a net margin of -2.36% compared to Ocular Therapeutix's net margin of -283.74%. Kiniksa Pharmaceuticals' return on equity of -7.31% beat Ocular Therapeutix's return on equity.Company Net Margins Return on Equity Return on Assets Ocular Therapeutix-283.74% -45.18% -30.87% Kiniksa Pharmaceuticals -2.36%-7.31%-5.95% Do analysts prefer OCUL or KNSA? Ocular Therapeutix presently has a consensus price target of $16.71, suggesting a potential upside of 90.37%. Kiniksa Pharmaceuticals has a consensus price target of $36.60, suggesting a potential upside of 72.56%. Given Ocular Therapeutix's higher probable upside, analysts plainly believe Ocular Therapeutix is more favorable than Kiniksa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocular Therapeutix 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Kiniksa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryOcular Therapeutix and Kiniksa Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Kiniksa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KNSA vs. The Competition Export to ExcelMetricKiniksa PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.53B$6.44B$5.06B$8.82BDividend YieldN/A8.11%5.17%4.07%P/E Ratio-151.4910.79125.9917.81Price / Sales3.99243.721,180.3874.38Price / CashN/A22.1633.8232.53Price / Book3.405.474.684.68Net Income$14.08M$153.61M$119.54M$226.08M7 Day Performance-6.23%-4.32%-2.45%-2.04%1 Month Performance-19.23%-8.61%-4.06%0.06%1 Year Performance33.90%28.79%29.86%24.60% Kiniksa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KNSAKiniksa Pharmaceuticals1.9939 of 5 stars$21.21+1.9%$36.60+72.6%+33.9%$1.50B$270.26M-151.49220OCULOcular Therapeutix3.7464 of 5 stars$8.78-1.6%$16.71+90.4%+273.6%$1.40B$58.44M0.00267INVAInnoviva1.0402 of 5 stars$19.15+0.3%N/A+40.6%$1.20B$310.46M27.75112News CoverageHigh Trading VolumeARQTArcutis Biotherapeutics1.7417 of 5 stars$10.18+0.9%$15.50+52.3%+391.8%$1.18B$59.61M0.00150SUPNSupernus Pharmaceuticals2.3042 of 5 stars$36.12+1.7%$36.00-0.3%+32.3%$1.96B$607.52M33.76580Positive NewsPLRXPliant Therapeutics3.4847 of 5 stars$12.73-0.5%$40.57+218.7%-11.4%$778.32M$1.58M0.0090BPMCBlueprint Medicines2.713 of 5 stars$94.81+0.2%$122.11+28.8%+43.9%$6.01B$249.38M0.00640Analyst ForecastAnalyst RevisionNUVLNuvalent2.1777 of 5 stars$91.17+0.1%$112.60+23.5%+51.1%$5.90BN/A0.0040VKTXViking Therapeutics4.7696 of 5 stars$51.53+0.0%$109.80+113.1%+337.8%$5.74BN/A0.0020Analyst ForecastGap UpLNTHLantheus4.5969 of 5 stars$86.45+8.8%$122.50+41.7%+25.1%$5.52B$1.30B14.38834Positive NewsGap UpRNAAvidity Biosciences2.3883 of 5 stars$43.65+0.9%$63.22+44.8%+631.2%$5.16B$9.56M0.00190Insider TradeAnalyst Revision Related Companies and Tools Related Companies Ocular Therapeutix Alternatives Innoviva Alternatives Arcutis Biotherapeutics Alternatives Supernus Pharmaceuticals Alternatives Pliant Therapeutics Alternatives Blueprint Medicines Alternatives Nuvalent Alternatives Viking Therapeutics Alternatives Lantheus Alternatives Avidity Biosciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KNSA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KNSA Stock Alerts